Budapest, Hungary

Zsuzsanna Mohai

This inventor holds 1 USPTO granted patent. Top assignee: Gyogyszerkutato Intezet Kft.. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zsuzsanna Mohai. Retrieved from https://idiyas.com/inventor/zsuzsanna-mohai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zsuzsanna Mohai: Innovator in Pharmaceutical Research

Introduction

Zsuzsanna Mohai is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that have therapeutic potential.

Latest Patents

Zsuzsanna Mohai holds a patent for (3R)-3-amino-4-carboxybutyraldehyde derivatives, which are known to inhibit the release of interleukin-1 beta. This innovation showcases his commitment to advancing medical science and improving treatment options.

Career Highlights

He is currently associated with Gyogyszerkutato Intezet Kft., where he continues to engage in groundbreaking research. His work has been instrumental in exploring new avenues for drug development.

Collaborations

Zsuzsanna has collaborated with esteemed colleagues such as Sandor Bajusz and Iren Veghelyi, contributing to a dynamic research environment that fosters innovation.

Conclusion

Zsuzsanna Mohai's contributions to pharmaceutical research and his innovative patents highlight his role as a key figure in the field. His work continues to inspire advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…